Tokyo-based Eisai Co Ltd will present eight poster presentations, including the latest data on its in-house discovered orexin receptor antagonist lemborexant (Dayvigo) at SLEEP 2023.
Major poster presentations include new data about the effects of lemborexant on obstructive sleep apnea (poster numbers: #298, 299, and 300).
“Eisai considers neurology, including insomnia, a therapeutic area of focus. Eisai strives to create innovative products as soon as possible in therapeutic areas with high unmet medical needs and will further contribute to addressing the diverse needs of, as well as increasing the benefits provided to, those living with neurological diseases and their families,” according to a release from the company.
SLEEP 2023 poster presentations are as follows (time ET):
- Poster #297 (Monday, June 5, 12 – 1:15 pm): Long-term Efficacy of Lemborexant on Objective Sleep Measures in Clinical Practice
- Poster #298 (Monday, June 5, 5 – 6 pm): Effect of Lemborexant on Sleep Architecture in Subjects with Comorbid Insomnia and Mild Obstructive Sleep Apnea from a Ph 3 Trial
- Poster #299 (Monday, June 5, 12 – 1:15 pm): The Effect of Lemborexant on Polysomnographic Sleep Parameters in Adults with Mild, Moderate, or Severe Obstructive Sleep Apnea
- Poster #300 (Monday, June 5, 5 – 6 pm): Effect of Lemborexant on Sleep Architecture in Adult and Elderly Subjects with Mild to Severe Obstructive Sleep Apnea
- Poster #301 (Monday, June 5, 12 – 1:15 pm): Shifts in Daytime Functioning Items on the Insomnia Severity Scale with Lemborexant after 6 Months of Treatment
- Poster #302 (Monday, June 5, 5 – 6 pm): Differential Effect of Lemborexant and Zolpidem on Wake Across the Night in Patients with Insomnia Disorder
- Poster #303 (Monday, June 5, 12 – 1:15 pm): Impact of Lemborexant on Daytime Ratings of Sleepiness/Alertness in Subjects with Insomnia Disorder and Baseline Sleepiness
- Poster #248 (Monday, June 5, 5 – 6 pm): Burden of Narcolepsy in Japan: A Nationwide Real-world Database Study from The Perspectives of Direct Medical Cost and Comorbidity
Lemborexant, an orexin receptor antagonist, is Eisai’s in-house discovered and developed small molecule that inhibits orexin neurotransmission by binding competitively to the two subtypes of orexin receptors (orexin receptor 1 and 2). Fast on/off receptor kinetics of lemborexant to orexin receptors may influence lemborexant’s potential to facilitate improvements in sleep onset and maintenance with minimal morning residual effects.
It has been approved for the treatment of insomnia in over 15 countries including Japan, the United States, Canada, Australia, and countries in Asia.